Ruconest not checked
IMMUNOe Research Centers · C1-esterase inhibitor
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Post SARS-CoV2 (COVID-19), Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), COVID - 19
- Main trialPhase 4
- “Assessment of RUCONEST (C1 Esterase Inhibitor \[Recombinant\]) in Alleviating Neurological Symptoms Linked to Infectious Pathogens”In the company’s words, NCT07932002 on ClinicalTrials.gov
- Other names
- C1-esterase inhibitor
Other drugs for COVID - 19
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up1
- 31 Jul 2027Phase 4 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovNew trial: none to Phase 4 · ClinicalTrials.gov NCT07932002
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 31 Jul 2027 | Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens | |
| Phase 4Completed | 1 Dec 2019 | A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions | |
| Phase 2Completed | 30 Mar 2024 | Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026